Table 3.
Results of meta-analysis
| Tests of homogeneity | Tests of publication bias | ||||||
|---|---|---|---|---|---|---|---|
| No. of studies | Pooled effect estimate RR (95% CI) | Q-value (d.f.) | P-value | I2 | Begg's P-value | Egger's P-value | |
| All studies | 14 | 0.85 (0.64, 1.12) | 45.0 (13) | <0.001 | 71% | 0.91 | 0.70 |
| RCTs | 6 | 0.92 (0.72, 1.16) | 5.3 (5) | 0.38 | 6% | 0.99 | 0.48 |
| RCTs of lipophilic statins | 4 | 1.04 (0.79, 1.37) | 3.0 (3) | 0.40 | 0% | 0.73 | 0.26 |
| RCTs of lipophobic statins | 2 | 0.72 (0.49, 1.06) | 0.1 (1) | 0.82 | 0% | 0.99 | – |
| Observational studies | 8 | 0.83 (0.53, 1.29) | 38.1 (7) | <0.001 | 82% | 0.54 | 0.66 |
| Case–control studies | 7 | 0.82 (0.47, 1.41) | 37.5 (6) | <0.001 | 84% | 0.76 | 0.66 |
| Cohort studies | 1 | 0.88 (0.60, 1.29) | – | – | – | – | – |
RR, Relative risk; CI, confidence interval; d.f., degrees of freedom, RCT, randomized controlled trial.